Bio Blast Pharma Ltd. (NASDAQ: ORPN) is a clinical-stage biotechnology company committed to developing clinically meaningful therapies for patients with rare and ultra-rare genetic diseases. Established in 2012, the company is quickly building a diverse portfolio of product candidates with the potential to address unmet medical need for incurable rare diseases. For more information, visit the company’s website at www.bioblast-pharma.com.